In executive orders released July 24, the Trump administration renewed its push toward a signature campaign issue: lowering drug prices. However, experts say that the orders are a rehash of similar proposals by the administration that failed to gain backing from either political party in 2019, and they are skeptical of the idea that the orders will actually lower prices. The three executive orders call for regulations allowing drugs to be imported from other countries, requiring Federally Qualified Health Centers (FQHCs) to make insulin and epinephrine available to low-income members of the public at the discounted prices set by the 340B Drug Pricing Program, and removing safe harbor protections under the Anti-Kickback Statue for prescription drug rebates in Medicare Part D.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.